Read this! This sums it up for Cardiol. Up up! Cardiol Therapeutics have insanely high potential with their CV treatments.
(**TSX: CRDL**)
Cardiol Therapeutics is doing some really amazing work with CBD and cardiovascular diseases. As we learn more and more about CBD, researchers are beginning to find new qualities that can be used as treatments for diseases that have limited treatment options. Cardiol is far from the first copmany to explore the curative qualities of CBD however, they are applying it to a very particular subset of conditions that are sure to make them stand out from similar competitors.
The main quality of CBD that Cardiol is looking to capitalize on is its anti-inflammatory properties. Many external research groups have studied and provided proof that in the right formulations, it can largely reduce inflammation in the cardiovascular system, which often is a precursor or symptom of many serious heart diseases. The JACC and Molecular Medicine have found that this effect decreases cardiac fibrosis and overall protects against cardiac injury.
What is an example of a disease that can cause or worsen cardiac injury? How about what has been plaguing the world for nearly 2 years now, COVID-19. Studies have shown that people who get COVID-19 who have dealt with pre-existing heart conditions are far more likely to show serious or possibly fatal side effects. This is obviously a very time-sensitive matter so Cardiol has been hard at work creating their CardiolRx Formulation to treat this issue. This treatment could be used as a preventative measure for at-risk individuals or as a treatment to lessen cardiac stress and injury. This treatment has received FDA approval and is currently in Phase II/III testing.
They also believe that CardiolRx is a strong candidate to receive Orphan Drug Status and funding. This is government funding that is given to pharmaceutical companies when they are developing treatments for rare diseases. Since there likely will not be a huge market for them, they are funded to still promote development. Cardiol believes that their treatment can also be used to combat Acute Myocarditis, a rare heart infection that is apparent in children and young adults. For this treatment, they have completed phase I testing and are working towards phase II.
A final and perhaps most marketable use for CardiolRx is in treating diastolic heart failure. This is by far one of the most common heart conditions there is and despite this, there have been very few advancements in treatments for a significant amount of time. This treatment is in the pre-clinical stages as it is a subcutaneous administration method that requires additional testing, but when clinical trials are complete down the road, this could be a game-changer for this common condition. It could largely reduce the severity and fatality of this horrible disease.
If this type of research and treatment intrigues you at all, I highly recommend checking out Cardiol Therapeutics. They are a penny stock that could show some serious growth as they advance towards the commercialization of their treatments.
Look into them yourselves, this could be a multi bagger over the next year. This is not investment advice!